Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Tots els drets reservats
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/218506
Engraftment characterization of risk-stratified AML in NSGS mice
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Disease heterogeneity is well documented, and patient stratification determines treatment decisions. Patient-derived xenografts (PDXs) from risk-stratified AML are crucial for studying AML biology and testing novel therapeutics. Despite recent advances in PDX modeling of AML, reproducible engraftment of human AML is primarily limited to high-risk (HR) cases, with inconsistent or very protracted engraftment observed for favorable-risk (FR) and intermediate-risk (IR) patients. We used NSGS mice to characterize the engraftment robustness/kinetics of 28 AML patient samples grouped according to molecular/cytogenetic classification and assessed whether the orthotopic coadministration of patient-matched bone marrow mesenchymal stromal cells (BM MSCs) improves AML engraftment. PDX event-free survival correlated well with the predictable prognosis of risk-stratified AML patients. The majority (85-94%) of the mice were engrafted in bone marrow (BM) independently of the risk group, although HR AML patients showed engraftment levels that were significantly superior to those of FR or IR AML patients. Importantly, the engraftment levels observed in NSGS mice by week 6 remained stable over time. Serial transplantation and long-term culture-initiating cell (LTC-IC) assays revealed long-term engraftment limited to HR AML patients, fitter leukemia-initiating cells (LICs) in HR AML samples, and the presence of AML LICs in the CD34 leukemic fraction, regardless of the risk group. Finally, orthotopic coadministration of patient-matched BM MSCs and AML cells was dispensable for BM engraftment levels but favored peripheralization of engrafted AML cells. This comprehensive characterization of human AML engraftment in NSGS mice offers a valuable platform for in vivo testing of targeted therapies in risk-stratified AML patient samples.
Matèries
Matèries (anglès)
Citació
Citació
LAPILLONNE, Helene, DÍAZ DE LA GUARDIA, R., VELASCO-HERNANDEZ, Talia, GUTIÉRREZ-AGÜERA, Francisco, ROCA-HO, Heleia, MOLINA, Òscar, NOMBELA-ARRIETA, Cesar, BATALLER TORRALBA, Alex, FUSTER, José luis, ANGUITA, Eduardo, VIVES, Susana, ZAMORA, Lurdes, NOMDEDÉU GUINOT, Josep francesc, GÓMEZ CASARES, María teresa, RAMÍREZ-ORELLANA, Manuel, RAMOS-MEJÍA, Verónica, RODRIGUEZ-MANZANEQUE ESCRIBANO, Juan carlos, BUENO, Clara, LOPEZ MILLAN, Maria belén, MENÉNDEZ, Pablo. Engraftment characterization of risk-stratified AML in NSGS mice. _Blood Advances_. 2021. Vol. 5, núm. 23, pàgs. 4842-4854. [consulta: 22 de gener de 2026]. ISSN: 2473-9529. [Disponible a: https://hdl.handle.net/2445/218506]